NASDAQ:GTBP
GT Biopharma, Inc.
GT Biopharma, Inc. reported net income of −$28.4M in fiscal 2025. The diluted share count rose 190.6%.Summary generated from GT Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−1377.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+190.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −58 | −21 | −14 | −14 | −12 |
| Net income | −58 | −21 | −8 | −13 | −28 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- S-1Registration statement
Oct 9, 2026 - 8-KOther events
Sep 25, 2026 - 8-KEntry into a material agreement
Sep 21, 2026 - 8-KEntry into a material agreement
Sep 15, 2026 - 8-KAmendment to articles or bylaws
Sep 3, 2026 - 8-KResults of a shareholder vote
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - DEF 14AProxy statement
Jul 2, 2026